SBFMSunshine Biopharma, Inc.
The schedule
- Thu15Oct
Over the next year, Sunshine Biopharma, Inc. may pursue a strategic partnership or licensing agreement on one of its development programs or commercial products to offset funding pressure. If by around October 2026 the company can announce a credible deal with upfront cash, milestones, or co-development support, the stock could re-rate from $0.55 toward $0.80, whereas a lack of partnering progress or a perceived weak deal structure could reinforce funding concerns and keep the shares closer to $0.45.
- Tue10Nov
- Thu31Dec
If Sunshine Biopharma, Inc. remains near or below $1.00 into late 2026, Nasdaq minimum bid price rules may force a formal compliance plan, potentially including a reverse stock split. From a base of $0.65, a constructive outcome, such as regaining compliance organically or obtaining an extension without an immediate split, could leave the stock around $0.70, whereas a reverse split combined with ongoing dilution or weak fundamentals could erode confidence and send shares toward $0.70.
- Tue11May
Q3 2026 earnings for Sunshine Biopharma, Inc. will provide a near year-end checkpoint on revenue trends, operating leverage, and how any financing or partnership activity has reshaped the company’s runway. From a base price of $0.80, a quarter showing stable revenue, disciplined costs, and visibility into funded operations through at least late 2027 could support a move toward $0.92, while weaker revenue, rising losses, or a shorter implied runway would likely push the stock down toward $0.92.
- Tue10Aug
Past
- Tue11Aug
Actual outcome: Bull
Sunshine Biopharma reported in-line Q2 EPS of -$0.46, but shares ultimately surged past the $0.82 bull target to reach $1.13. The strong upward revaluation was driven by major commercial milestones announced just prior to the print, including Canadian regulatory approval for its generic Dienogest tablets and the launch of Amoxicillin shipments to Canadian pharmacies, which bolstered confidence in the company's expanding revenue trajectory.
The Q2 2026 report for Sunshine Biopharma, Inc. will update the trajectory of its specialty and generic drug revenue base and provide detail on R&D progress in its oncology and other development programs. From a base of $0.70, a print showing stable or improving revenue, controlled expenses, and a clear roadmap for key studies could lift the shares toward $0.82, while further revenue erosion, widening losses, or vague R&D timelines would likely send the stock toward $0.82.
- Fri31Jul
Actual outcome: Bull
Sunshine Biopharma's stock exceeded the bull target, reaching $1.13, driven by a series of positive commercial and regulatory developments rather than equity financing news. The company secured Canadian regulatory approvals for its generic Dienogest and Ondansetron tablets, and successfully launched pharmacy shipments of Amoxicillin in Canada. These advancements into multi-billion dollar markets overshadowed dilution concerns and fueled the bullish price action.
With Sunshine Biopharma, Inc. burning cash and operating at a loss, the company is likely to access the equity markets over the next few quarters. Around mid-2026, investors should be prepared for a potential secondary offering or at-the-market program that could pressure the stock from $0.85, with a well-structured, modestly dilutive raise holding the price near $0.95, while a highly dilutive deal or one priced at a large discount could drive shares toward $0.95.
